Program Learning Objectives
- Summarize recent updates in cancer immunotherapy for lung cancer and toxicity management for key disease states.
- Implement cancer immunotherapy for lung cancer into clinical practice appropriately.
- Describe management approaches for difficult or refractory immune-related adverse events.
- Describe the use of biomarkers to select appropriate cancer immunotherapies for lung cancer patients.
The Advances in Cancer Immunotherapy™ (ACI) programs aim to reach practicing clinical oncologists, nurses, nurse practitioners, advanced practitioners, pharmacists, emergency physicians, and other allied health professionals who wish to learn the basic principles of cancer immunotherapy and the most up-to-date clinical data for these treatments, in a multitude of disease states/therapeutic areas, in order to inform and integrate into their own clinical practice. In-training oncologists and hospital administrators will also find the program beneficial.
Case Study Submission Information
As part of the program, registrants are encouraged to submit case studies for expert review during the case study panel concluding the program. If you are interested in taking advantage of this opportunity, please review and sign the linked case study guidelines, and return your case study and signed guidelines to email@example.com.